학술논문
Combination of intravenously delivered cavatak (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and tumor rechallenge
Document Type
Report
Author
Source
Journal for ImmunoTherapy of Cancer. November 4, 2015, Vol. 3 Issue Suppl 2
Subject
Language
English
ISSN
2051-1426
Abstract
Author(s): Min Yuan[sup.1] , Yvonne Wong[sup.1] , Gough Au[sup.1] and Darren Shafren[sup.2] Background Coxsackievirus A21 (CAVATAK[sup.TM] ) is a bio-selected oncolytic immunotherapy virus. Following intravenous (i.v) administration, CAVATAK can preferentially [...]